Skip to content

Earnings yield at other companies

Amgen logo
AmgenAMGN
4.1%+0.6pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-21.3%
Nuvation Bio logo
Nuvation BioNUVB
-9.8%-4.6pp
Regenxbio logo
RegenxbioRGNX
-67.1%+73.5pp
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
22.7%+15.1pp
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
1%+0.5pp

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K
Free cash flow-$22.0M

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%

Returns & leverage

See full
Return on equity174.1%
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Calculated from Rigel Pharmaceuticals’s reported figures.

Based on trailing twelve months.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's earnings yield.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's earnings yield?
Rigel Pharmaceuticals (RIGL) reported earnings yield of 72.9% in Q1 2026.
How has Rigel Pharmaceuticals's earnings yield changed year-over-year?
Rigel Pharmaceuticals's earnings yield increased by 530.3% year-over-year, from 11.6% to 72.9%.
What is the long-term trend for Rigel Pharmaceuticals's earnings yield?
Over 5 years (2020 to 2025), Rigel Pharmaceuticals's earnings yield has grown at a 56.9% compound annual growth rate (CAGR), from -5% to 47.2%.
What does earnings yield mean?
Trailing-twelve-month net income divided by market capitalization at the quarter end — the inverse of the P/E ratio, expressed as a percentage.